Analisis Efektivitas Biaya Pengobatan Diabetes Melitus Tipe 2 Pada Pasien Rawat Jalan Di Rsud Dr. Moewardi Tahun 2018

DEWI PERMATASARI, FITRIA and , Mariska Sri Harlianti, MSc., Apt (2019) Analisis Efektivitas Biaya Pengobatan Diabetes Melitus Tipe 2 Pada Pasien Rawat Jalan Di Rsud Dr. Moewardi Tahun 2018. Skripsi thesis, Universitas Muhammadiyah Surakarta.

	PDF (Naskah Publikasi) Naskah Publikasi Untuk Perpus Pusat OK FIX.pdf Download (935kB)
	PDF (Lampiran) Lampiran NasPub.pdf Restricted to Repository staff only Download (2MB) | Request a copy
	PDF (Surat Pernyataan Publikasi) Surat Pernyataan Publikasi.pdf Restricted to Repository staff only Download (248kB) | Request a copy

Abstract

Diabetes Melitus (DM) is one of the diseases whose the incidence rate is very high in Indonesia. In 2030, it is predicted that the risk of developing type 2 DM will increase in people aged >65 years old up to 82 million people in the developing countries such as Indonesia. This increased incidence rate can add to the expenses incurred by the government for the treatments of the type 2 DM up to USD 1.27 billion which can happen in 2020. The aim of this research was to analyze the most cost-effective cost effectiveness in the treatments of the type 2 DM outpatients at Regional Public Hospital (RSUD) of Dr. Moewardi in 2018. This research was conducted by using non-experimental method retrospectively with 97 people fulfilling the inclusion criteria. The inclusion criteria in the research were type 2 DM outpatients aged ≥18 years old, patients undergoing treatments with internist polyclinics and general polyclinics for 3 months with the same treatments, type 2 DM patients with or without comorbidities, patients having complete medical record data and BPJS patients at RSUD Dr. Moewardi. The samples were taken by using purposive sampling technique. The cost effectiveness analysis was done by using the ACER and ICER parameters. The results showed that the most cost-effective treatments of the type 2 DM were Lantus® and a combination of Lantus® and Apidra® having ACER values of Rp 9.538,25 and Rp 23.633,27, respectively, and ICER values of Rp 923,95 and Rp 4.734,04, respectively. The Metformin therapy and a combination therapy of Metformin and Glimepiride have ACER values of Rp 9,827.71 and Rp 8,561.60, respectively, and ICER values of Rp 6,987.73 and Rp - , respectively.

Item Type:	Karya ilmiah (Skripsi)
Uncontrolled Keywords:	Diabetes Melitus, cost effectiveness, ACER, ICER.
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Fakultas Farmasi > Farmasi
Depositing User:	FITRIA DEWI PERMATASARI
Date Deposited:	13 Feb 2019 02:55
Last Modified:	13 Feb 2019 02:55
URI:	http://eprints.ums.ac.id/id/eprint/71140

Actions (login required)

View Item